Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 vs T-DM1 in HER2-positive breast cancer with residual disease after neoadjuvant therapy
NCT06830889Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Oct 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1 in breast cancer, sponsored by Biokin Pharmaceutical. Started Jun 2025; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06830889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830889.